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Abstract
Background: Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease worldwide. Renin-
angiotensin system (RAS) inhibitors are the first-line treatment for diabetic patients with hypertension. However,
whether RAS inhibitors prevent the development of DKD remains controversial. We conducted a retrospective
cohort study quantifying the preventive effect of antihypertensive treatment with RAS inhibitors on DKD, using data
from specific health check-ups and health insurance claims.
Methods: The study subjects were 418 patients with diabetes and hypertension, drawn from health insurance
societies located in Fukuoka and Shizuoka prefectures in Japan. The subjects were divided into three groups,
according to the type of antihypertensive treatment they received. They were then compared in terms of the
development of DKD, using the diagnostic codes from ICD-10.
Results: Thirty subjects (6.2 %) developed DKD during the study period between April 2011 and September 2013.
RAS inhibitor treated group showed a significantly lower risk of DKD [adjusted odds ratio (AOR) = 0.35; 95 %
confidential interval (CI): 0.16–0.76] compared with the no treatment group.
Conclusion: We conclude that antihypertensive treatment with RAS inhibitors is potentially useful for preventing
the development of DKD.
Background
Diabetes mellitus (DM) is the leading cause of chronic
kidney disease (CKD) worldwide [1]. Defined as having a
decreased glomerular filtration rate or elevated urine
albumin excretion level, CKD is a major risk factor for
cardiovascular diseases as well as end-stage renal disease
(ESRD) [2]. The prognosis for diabetic patients is
worsened when complicated with CKD. Therefore,
special attention has recently been paid to this complica-
tion, defined as diabetic kidney disease (DKD) [3, 4].
The progression of DKD is associated with substantial
morbidity, mortality, and costs. Therefore, its prevention
and management have been increasingly recognized as
being important for clinical care, disease management,
and public health.
Although the mechanism underlying the development
of DKD is still unknown, it is widely accepted that the
treatment of hypertension is as important as optimal
glycemic control in preventing the development of DKD
among diabetic patients [5]. Many studies have demon-
strated that renin-angiotensin system (RAS) inhibitors
such as angiotensin receptor blockers (ARBs) and
angiotensin converting enzyme inhibitors (ACE-Is) slow
the rate of progression of DKD and reduce the incidence
of cardiovascular disease and ESRD [6–9]. However,
whether RAS inhibitors prevent the development of DKD
remains controversial [10–14].
Currently, the guidelines for the management of hyper-
tension in Japan [15], as well as the United States [16, 17]
and Europe [18], recommend RAS inhibitors as first-line
treatment for diabetic patients with hypertension.
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However, the proportion of RAS inhibitors used clinically
in diabetic patients remains unclarified. Moreover, the de-
gree to which RAS inhibitors reduce the risk of DKD has
not been fully investigated. Therefore, we conducted a
retrospective cohort study quantifying the effect of antihy-
pertensive treatment with RAS inhibitors on the preven-




We identified 16,804 beneficiaries aged ≥ 40 years as of
March 31, 2011, who worked for health insurance soci-
eties located in the Japanese prefectures of Fukuoka and
Shizuoka, and attended specific health check-ups in the
2010 fiscal year (FY). From this population, we identified
1022 subjects whose hemoglobin A1c (HbA1c) level
[taken from the national glycohemoglobin standardization
program (NGSP)] was ≥ 6.5 %, and/or who were receiving
treatment for diabetes. Next, we excluded 522 subjects
without hypertension. Subjects with hypertension were
identified as those using antihypertensive drugs and/or
having a systolic blood pressure (SBP) of ≥140 mmHg or
diastolic blood pressure (DBP) of ≥90 mmHg. Blood pres-
sure was determined from the average of two consecutive
measurements, separated by 30 s and after 5 min of rest.
Owing to the nature of the health checkup, blood pressure
was only measured on the day of the checkup. We also ex-
cluded 57 subjects diagnosed as having stroke, chronic
heart disease, CKD, or anemia, and 25 subjects whose
health insurance claim data indicated a diagnosis of kidney
disease between January and March 2011. Unfortunately,
as this retrospective study was conducted using adminis-
trative data, only those with a diagnosed kidney disease
were excluded. Finally, we obtained 418 study subjects
(Fig. 1). The study was in compliance with the Helsinki
Declaration and approved by the Kyushu University Insti-
tutional Board for Clinical Research (25–340).
Main outcome
The main outcome in this study was the development of
DKD. DKD was defined as diabetes with the presence of
albuminuria, decreased GFR, or both. We identified pa-
tients with DKD between April 2011 and September
2013 on the basis of the diagnostic codes from the Inter-
national Classification of Diseases, 10th Revision (ICD-
10) (Table 1).
Definition of variables
Subjects whose HbA1c values were ≥6.5 %, or who were
receiving diabetic treatment in FY 2010 were defined as
having DM. Ages were categorized into three groups:
40–49 years, 50–59 years, and ≥60 years. Baseline
HbA1c levels were categorized into three groups: ≤7.0,
7.1–8.0, and ≥8.1.
We divided the subjects into three groups, according
to the type of antihypertensive treatment and compared
the groups in terms of the development of DKD after
2.5 years of follow-up. The ‘no treatment’ group included
hypertensive patients who were untreated. The RAS
treatment group included those who had received anti-
hypertensive treatment with RAS inhibitors. The RAS
inhibitors included ARBs and ACE-Is. Although the dir-
ect renin inhibitor is also categorized as a RAS inhibitor,
none of the patients received the drug in this study. The
non-RAS treatment group included those who had re-
ceived treatment other than RAS inhibitors such as cal-
cium channel blockers, beta blockers, alpha blockers,
and diuretics.
Fig. 1 Inclusion and exclusion flowchart. DM; diabetes mellitus,
CHD; coronary heart disease, CKD; chronic kidney disease
Table 1 Definition of diabetic kidney disease and International
Classification of Diseases, 10th revision
Code Description
ICD E102 Type 1 DM with incipient diabetes nephropathy
ICD E112 Type 2 DM with incipient diabetes nephropathy
ICD E142 Unspecified DM with incipient diabetes nephropathy
ICD N083 Glomerular disorders in diabetes mellitus
ICD N180 End-stage renal disease
ICD N189 Chronic kidney disease, unspecified
ICD I129 Hypertensive chronic kidney disease
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Statistical analyses
Subject characteristics were summarized using frequencies
and proportions for categorical variables and median and
interquartile ranges for continuous variables. The categor-
ical variables were compared between the three groups
using Pearson’s chi-square test, and the continuous vari-
ables were compared between the three groups using the
Kruskal-Wallis test.
Multiple logistic regression analyses were carried out to
estimate adjusted odds ratios (AORs) and 95 % confidence
intervals (CIs) for the development of DKD. We set the
development of DKD as the dependent variable, and cate-
gorized age, gender, HbA1c level, prefecture, and treat-
ment type for hypertension as independent variables.
Statistical analyses were performed using IBM SPSS
Statistics for Windows, Version 20.0 (IBM Corp.,
Armonk, NY, USA). P values <0.05 were regarded as sta-
tistically significant.
Results
We identified 136 patients in the no treatment group, 11
patients in the non-RAS treatment group, and 271 pa-
tients in the RAS treatment group. Baseline characteristics
are presented in Table 2, stratified according to the type of
antihypertensive treatment. There were no significant
differences in age, age category, gender, prefecture, or
median BMI among the three groups. Distributions of
HbA1c level, SBP, and DBP were significantly different
among the three groups. Additionally, there were no sig-
nificant differences in the proportions of subjects with
hypercholesterolemia and the smoking.
During the follow-up period, 16 (11.8 %), 2 (22.2 %),
and 12 (4.4 %) subjects developed DKD in the no treat-
ment, non-RAS treatment, and RAS treatment groups,
respectively. Table 3 shows the results of multiple logis-
tic regression analyses. The RAS treatment group had a
significantly lower risk of DKD (OR = 0.35; 95 % CI
0.16–0.76, AOR = 0.37; 95 % CI: 0.16–0.83) than the no
treatment group. In contrast, the non-RAS treatment
group had a higher risk of DKD (OR = 1.67; 95 % CI:
0.33–8.41, AOR = 2.40; 95 % CI: 0.43–13.48) than the no
treatment group, although this difference was not statis-
tically significant.
Discussion
Our results indicated that among diabetic patients with
hypertension, antihypertensive treatment with RAS in-
hibitors significantly reduced the risk of developing
DKD. To the best of our knowledge, this is the first
study using the combination of data from specific health
check-ups and health insurance claims to evaluate the
preventive effect of RAS treatment on DKD.
Our results are consistent with previous studies showing
that RAS inhibitors reduced the likelihood of developing
DKD among diabetic patients with hypertension [8, 14]. It
is assumed that RAS inhibitors prevent the development
Table 2 Subject characteristics according to treatment groups
Total No treatment Non-RAS treatment RAS treatment P-value
(N = 418) (N = 136) (N = 11) (N = 271)
Median age [IQR] 53[9] 53[11] 52[17] 53[9] 0.944a
Age 40–49 103(25 %) 40(29.4 %) 3(27.3 %) 60 (22.1 %)
50–59 233(56 %) 70(51.5 %) 4(36.4 %) 159(58.7 %) 0.268
60≤ 82(20 %) 26(19.1 %) 4(36.4 %) 52(19.2 %)
Gender Male 361(86 %) 122(89.7 %) 9(81.8 %) 230(84.9 %) 0.369
Female 57(14 %) 14(10.3 %) 2(18.2 %) 41(15.1 %)
Prefecture Fukuoka 198(47 %) 72(52.9 %) 6(54.5 %) 121(44.6 %) 0.315
Median BMI, kg/m2 [IQR] 26.1[4.6] 26.2[44] 24.8[4.2] 26.1[4.6] 0.302a
Median WC, cm [IQR] 90.3[13] 90.2[12.5] 87.5[10] 90.5[12.5] 0.368a
Median SBP, mmHg [IQR] 142[19] 146[12] 139[31] 138[22] 0.001a
Median DBP, mmHg [IQR] 88[14] 92[10] 82[20] 84[12] 0.001a
Median HbA1c, % [IQR] 7.1[1.5] 7.4[1.8] 6.5[0.6] 7.1[1.5] 0.001a
Median TGs, mg/dl [IQR] 139[106] 141.5[44] 139[73] 137[101] 0.94a
Median GGT, U/I [IQR] 54[58] 46[49] 44[76] 57[57] 0.153a
Hypercholesterolemia 734(33 %) 337(30.4 %) 143(34.2 %) 151(32.7) 0.389
Smoking 493(22 %) 211(19 %) 93(22.2 %) 122(26.4) 0.821
Numbers are median [IQR] or number (%), unless otherwise stated. IQR interquartile range
BMI body mass index, WC waist circumference, TGs triglycerides, GGT gamma-glutamyltransferase
aCompared using the Kruskal-Wallis test. Other comparisons made using Pearson's chi-square test
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of DKD by improving the hemodynamics of the kidney via
inhibition of angiotensin II overactivity [19].
RAS inhibitors were used for 96 % of the antihypertensive-
treated group, indicating a high rate of compliance with
the guidelines. However, 32.5 % of all the subjects with
hypertension were not treated for hypertension, despite
the fact that diabetic patients with hypertension are at
the highest risk of cardiovascular events [20]. The rea-
sons for this are not well understood. One possible rea-
son is that the subjects with hypertension in this study
may have included patients not actually hypertensive,
but with a one-off abnormal blood pressure reading. A
low hypertension treatment rate among diabetic pa-
tients has been similarly reported [21, 22]. Turchin
et al. suggested that shorter time intervals between
physician–patient encounters are associated with im-
proved blood pressure control [23]. In terms of disease
management in the future, a survey of consultation
rates of the patients, including oral examination, would
be necessary.
In June 2013, the Japanese government announced a
‘data health plan’ to be started in FY 2015. This plan will
encourage all insurers to engage in disease prevention
and health promotion programs based on administrative
data such as data from health insurance claims and spe-
cific health check-ups. The Ministry of Health, Labour
and Welfare will play a central role in promoting the
project. Administrative data should be analyzed to moni-
tor patient compliance and adherence to treatment, and
to determine whether medical treatment is based on the
guidelines. Furthermore, in terms of disease manage-
ment, health guidance by insurers may play an import-
ant role in encouraging consultations.
The non-RAS treatment group showed a higher preva-
lence of DKD than the no treatment group, although
this difference was not statistically significant. The find-
ing could be related to the type of antihypertensive drug
that they received; as in both cases, the subjects received
antihypertensive drugs with diuretics. It has been sug-
gested that diuretics cause DKD via the deterioration of
glycemic control.
This study has several limitations. First, we used ad-
ministrative data; thus, the confirmation of the develop-
ment of DKD depended on claims data, rather than
clinical data such as urine and blood test results. Second,
in this study, the regularity of patient visits and drug
compliance were not evaluated; these factors could be
related to the development of DKD. Third, the types of
RAS inhibitor were not considered. Several studies have
demonstrated that each RAS inhibitor has a different
mode of action and displays properties that may or may
not be replicated by any other RAS inhibitor [13, 24]. In
this regard, further studies are necessary to clarify the
details of RAS treatment, namely, ARB, ACE-I, or com-
bination therapy. Finally, the homogeneity of the study
group may limit the generalizability of our findings to
other racial and ethnic groups. Further evidence is
needed to corroborate our findings in other populations.
Conclusion
This study suggests that antihypertensive treatment with
RAS inhibitors is potentially useful for the prevention of
DKD among diabetic patients with hypertension.
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Table 3 Crude and adjusted odds ratios for DKD development
Total Subject developed DKD Subject did not develop DKD Unadjusted (95 % CI) Adjusteda (95 % CI) P-value
(N = 418) (N = 30) (N = 388)
No treatment 136(100 %) 16(11.8 %) 120(88.2 %) 1.00(reference) 1.00(reference)
Non-RAS treatment 11(100 %) 2(18.2 %) 9(81.8 %) 1.67(0.33 to 8.41) 2.40(0.43 to 13.48) 0.366
RAS-treatment 271(100 %) 12(4.4 %) 259(95.6 %) 0.35(0.16 to 0.83) 0.37(0.16 to 0.83) 0.015
aAdjusted by age, gender, prefecture, and HbA1c
Hosmer-Lemeshow goodness of fit: P = 0.151
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